Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript

Todd Tushla

Good morning, and good afternoon. My name is Todd Tushla, I’m the Vice President of Investor Relations at Neurocrine Biosciences. And on behalf of our entire company, welcome to our 2025 R&D Day, whether you’re here in person, on the webcast or reading the transcript, we’re grateful for your time. We will be making forward-looking statements today.

So I refer you to our latest SEC disclosures. Our speakers for today from Neurocrine will be Kyle Gano, Chief Executive Officer; Sanjay Keswani, our Chief Medical Officer; and Jude Onyia, our Chief Scientific Officer.

As far as tenure at Neurocrine, Sanjay joined us in June. Jude joined us in 2021, and Kyle joined us in 2001. Wow, that was a long time ago. We’re also fortunate to have with us today Dr. John Krystal, a world-leading expert in the field of neurology and psychiatry and a Professor at Yale University. Dr. Krystal, thank you for being here. Dr. Krystal will be joined on stage by Jaz Singh, our Vice President Of Neuropsychiatry Development for